COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Infliximab (Remicade) for Patients With Acute Kawasaki Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00271570
Recruitment Status : Completed
First Posted : January 2, 2006
Results First Posted : December 29, 2009
Last Update Posted : June 14, 2010
Centocor, Inc.
Information provided by:
University of California, San Diego

Brief Summary:
This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.

Condition or disease Intervention/treatment Phase
Kawasaki Disease Drug: Infliximab (Remicade) Biological: Intravenous immunoglobulin (IVIG) Phase 1

Detailed Description:
This study is an exploratory, pilot study to examine tolerance and pharmacokinetics of infliximab in infants and children with acute Kawasaki Disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Infliximab (Remicade) for Patients With Acute Kawasaki Disease Who Fail to Become Afebrile After Intravenous Gamma Globulin Therapy
Study Start Date : April 2004
Actual Primary Completion Date : October 2006
Actual Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kawasaki Disease

Arm Intervention/treatment
Active Comparator: Second Dose of IVIG (2g/kg)
Subjects who did not respond to the first dose of IVIG received a 2nd dose of IVIG in this arm (2g/kg)
Biological: Intravenous immunoglobulin (IVIG)
2nd dose of IVIG (2g/kg)
Other Name: Gammagard, Gamunex

Experimental: Infliximab (5mg/kg)
Remicade (5mg/kg) single dose
Drug: Infliximab (Remicade)
Remicade was 5 mg/kg IV (single dose)

Primary Outcome Measures :
  1. Number of Adverse Events (Focused on Side Effects From IVIG or Infliximab Administration) [ Time Frame: 2 weeks ]
    The safety of giving infliximab to treat IVIG-resistant Kawasaki disease was measured by recording the number of adverse events that occurred in each group. An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of either IVIG or infliximab, regardless of whether it was considered related to IVIG or infliximab, that occured during the course of this study.In particular we evaluated for AEs related to side effects from infliximab or IVIG.

  2. Area Under the Curve of Infliximab Concentration Before Infliximab Infusion and Then 2 and 24 Hours, 1 Week (5 to 9 Days), 2 Weeks (12 to 16 Days), and 4 Weeks (26 to 30 Days) After Infliximab Infusion) [ Time Frame: before infliximab infusion and then 2 and 24 hours, 1 week (5 to 9 days), 2 weeks (12 to 16 days), and 4 weeks (26 to 30 days) after infliximab infusion. ]
    The area under the curve (AUC) from time 0 to the last measurable concentration (AUC0-last) was estimated using the trapezoidal rule up to the last measurable concentration.Samples were collected before infliximab infusion and then at 2 and 24 hours, 1 week (5 to 9 days), 2 weeks (12 to 16 days), and 4 weeks (26 to 30 days) after infliximab infusion. Subjects with detectable infliximab concentrations at week 4 had another sample drawn at week 10 (68 to 72 days).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

To be eligible for the trial, subjects must meet all of the following criteria:

  1. All eligible subjects, or legal representative, must provide written informed consent/assent, prior to initiation of any study procedure.
  2. Eligible subjects will be infants and children, under 18 years old, with acute KD who remain or become febrile (>/= 38.3˚ C or 101.0˚ F) after the end of the 48 h-period after completing their IVIG infusion (2gm/kg).
  3. Patients must have persistent or reoccurrence of fever > 48 hours of observation to be eligible for the trial.
  4. Prior to the initial IVIG treatment, patients must have been febrile for >/= 3 days and have met 4/5 standard clinical criteria (Table 1) - OR - patients with fever and 3/5 clinical criteria will be eligible if echocardiogram demonstrates at least one coronary artery segment with a Z score of > 2.
  5. Patients must present for their initial diagnosis and IVIG treatment within the first 14 days after fever onset (Illness Day 14).
  6. Females of childbearing potential and males must be using adequate contraception (abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) throughout the trial.
  7. All eligible subjects must have a chest radiograph within one week prior to first infusion of study drug with no evidence of malignancy, infection or fibrosis.

Exclusion criteria

If a subject has any of the following criteria, he or she may not be enrolled in the study:

  1. Have been receiving corticosteroids (ie, via any route) at doses > 1 mg/kg prednisone equivalent daily.
  2. Have history of TB or TB exposure.
  3. Have history of histoplasmosis or coccidiomycosis.
  4. Have received anakinra (Kineret®), etanercept (Enbrel®), or adalimumab (Humira®) within 1 month prior to first study drug administration.
  5. Have any chronic disease, except asthma, atopic dermatitis or controlled seizure disorder.
  6. Have documented history of current active hepatitis B or a history of hepatitis C infection.
  7. Have documented history of human immunodeficiency virus (HIV) infection
  8. Have received a transplanted organ (with the exception of a corneal transplant performed > 3 months prior to first study drug administration).
  9. Have a known malignancy or history of malignancy within the 5-year period prior to first study drug administration (with the exception of squamous or basal cell carcinoma of the skin that has been completely excised without evidence of recurrence).
  10. Have a history of prior lymphoproliferative disease including lymphoma.
  11. Have multiple sclerosis or other central demyelinating disorder.
  12. Have received any previous treatment with infliximab or other monoclonal antibodies.
  13. Have used any investigational drug within 1 month prior to first study drug administration or within 5 half-lives of the investigational agent, whichever is longer.
  14. Are participating in another investigative trial, involving investigational agents, during participation in this trial.
  15. Have a history of substance abuse (drug or alcohol) within the previous 3 years.
  16. Are pregnant, nursing, or planning pregnancy (both men and women) during the trial or within the 6-month period thereafter.
  17. Have a known allergy to murine proteins or other chimeric proteins.
  18. Patients with ischemic congestive heart failure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00271570

Layout table for location information
United States, California
San Diego, California, United States, 92103
Sponsors and Collaborators
University of California, San Diego
Centocor, Inc.
Layout table for investigator information
Principal Investigator: Jane C Burns, M.D. UCSD/CHHC
Layout table for additonal information
Responsible Party: Jane C. Burns, University of California, San Diego Identifier: NCT00271570    
Other Study ID Numbers: 041374
First Posted: January 2, 2006    Key Record Dates
Results First Posted: December 29, 2009
Last Update Posted: June 14, 2010
Last Verified: November 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Mucocutaneous Lymph Node Syndrome
Vascular Diseases
Cardiovascular Diseases
Lymphatic Diseases
Skin Diseases, Vascular
Skin Diseases
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents